6-7 NEWS
Eli Lilly and HAYA in $1bn deal; Novartis’ Fabhalta recommended by NICE

8-9 NEWS
Sanofi’s BTK inhibitor shows promise in MS; UK government invests £400m into clinical research

10-11 DERMATOLOGY NEWS
FDA approves Galderma’s Nemluvio; Merck's ten-year results for melanoma

12 DARWIN'S MEDICINE
Medicine can be beyond reach – unless...

13 DELIVERING INCLUSIVE EVENTS
We also need to consider those disabilities that are not visible

14 INNOVATIVE IMPACT BLOG
The secrets of the pharmaceutical launch A-team

15 THE FUTURE OF HEALTHCARE COMMUNICATIONS
The future is full of potential – if we’re brave enough to experiment

16-17 WOMEN IN PHARMA
Iona Everson from PMGroup spoke to Ulrike Graefe-Mody, global head of retinal health at Boehringer Ingelheim, about her career path and how female representation in the industry has changed over the past two decades

20-22 ESMO 2024 – HOW PHARMA IS BREATHING LIFE INTO CANCER COMMS
The most interesting trend from a marketing perspective was the clear change of emphasis in the language of cancer, with companies across the space reframing the narrative to focus on ‘living’ rather than just ‘surviving’

24-25 SERVING UP CUSTOMER EXPERIENCE EXCELLENCE
This latest report on the state of customer experience in the global pharmaceutical industry involved 6,100 HCPs across 13 countries and eight therapy areas

28-30 PRECISION, PLANNING AND CREATIVITY FOR LAUNCH EXCELLENCE IN A VOLATILE SECTOR
Sticking to routines and mechanisms that served well over previous generations of launch will not insulate against the fierce failure rate of the current, volatile climate

32-34 COUNTDOWN TO A OPTIMISED DRUG LAUNCH: FIVE DETERMINANTS OF SUCCESS
The launch of a new pharmaceutical product depends on a host of determinants and it just takes one factor to send the launch awry

35 HEALTHCARE COMMS
Executive Insight opens New York office to better serve US biopharma clients; Wilmington Healthcare relaunches as HSJ Information

October 2024